Athersys has patented a method using expanded multipotent stem cells for treating various injuries and diseases without the need for immunosuppressive treatment. The cells can differentiate into different cell types and are not genetically engineered. The treatment excludes specific conditions like brain injury, diabetes, and multiple sclerosis. GlobalData’s report on Athersys gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Athersys, Human telomerase RT biomarker was a key innovation area identified from patents. Athersys's grant share as of May 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Method of administering multipotent stem cells without immunosuppressive treatment
A recently granted patent (Publication Number: US11992507B2) discloses a method for administering expanded multipotent stem cells to a subject in need. The method involves utilizing stem cells that are not embryonic or germ cells, can differentiate into various cell types, express telomerase, and have undergone multiple cell doublings in culture. These cells, derived from bone marrow, are allogeneic or xenogeneic to the subject, non-immunogenic, and have not been genetically engineered. Importantly, the method excludes the administration of immunosuppressive treatments and specifies that the cells are not intended for specific conditions such as brain injury, immune dysfunction, diabetes, graft versus host disease, or multiple sclerosis.
Furthermore, the patent details additional aspects of the method, including the dosage range for administering the cells per kilogram of the subject's mass, the potential co-administration of growth factors or antimicrobial agents, and the various routes of administration such as parenteral, intravenous infusion, or surgical implantation. The method also highlights the positive expression of oct-3/4 in the cells and emphasizes their derivation from human bone marrow. Overall, the patent provides a comprehensive framework for utilizing expanded multipotent stem cells in a subject without the need for immunosuppressive treatments, offering potential applications in regenerative medicine and beyond.
To know more about GlobalData’s detailed insights on Athersys, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
